Fulvestrant Injection
Product Images NDC 68462-317

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 18 technical images submitted to the FDA as part of the official labeling for Fulvestrant (NDC 68462-317). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Glenmark Pharmaceuticals Inc., Usa, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Ctn

Ctn
FDA Label Image

Figure1

Figure1
FDA Label Image

Figure10

Figure10
FDA Label Image

Figure11

Figure11
The text describes the censored observations of a study comparing the effects of Fulvestrant plus Abemacicib versus Fulvestrant plus Placebo. The study included 446 participants in the Fulvestrant plus Abemaciclib group and 223 participants in the Fulvestrant plus Placebo group. Time is also mentioned in months.*
FDA Label Image

Figure12

Figure12
The provided text represents a table that displays statistical data collected for two different treatments (Fulvestrant plus Abemaciclib and Fulvestrant plus Placebo) over a period of 57 months. The number of patients enrolled in each treatment is included in this table. Data is also provided for the number of censored observations, the number of patients at risk, and the time that has elapsed in months in the study for each treatment.*
FDA Label Image

Figure13

Figure13
FDA Label Image

Figure14

Figure14
FDA Label Image

Figure9

Figure9
FDA Label Image

Figure-2 (Figure 2)

Figure-2 (Figure 2)
FDA Label Image

Figure-3 (Figure 3)

Figure-3 (Figure 3)
FDA Label Image

Figure-4 (Figure 4)

Figure-4 (Figure 4)
FDA Label Image

Figure-5 (Figure 5)

Figure-5 (Figure 5)
FDA Label Image

Figure-6 (Figure 6)

Figure-6 (Figure 6)
The text shows a chart illustrating the Progression Free Survival of patients receiving Fulvestrant 250mg and Fulvestrant 500mg, in which the proportion of patients progress-free is represented against time. The chart indicates the number of patients at risk for each treatment at different time intervals.*
FDA Label Image

Figure-8 (Figure 8)

Figure-8 (Figure 8)
FDA Label Image

Figure7 (Figure7)

Figure7 (Figure7)
The text describes a graph showing the proportion of patients alive over time, with tick marks indicating censored observations. The graph compares two treatments, Fulvestrant 500mg and Fulvestrant 250mg, and shows the number of patients "at risk" for each treatment at various time points. The text notes that the results were not statistically significant as no adjustments were made for multiplicity.*
FDA Label Image

Image 01

Image 01
FDA Label Image
Logo (Logo)
FDA Label Image

Structure (Structure)

Structure (Structure)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.